iRhythm, best known for its Zio cardiac monitoring wearables, is moving to expand well beyond its 14-day-patch roots by acquiring wearable biosensor company VitalConnect for $287.5M.
- The deal breaks down into roughly $237.5M in cash with about $50M in iRhythm stock and is expected to close by the end of 2026.
- It’s one of the bigger monitoring acquisitions in recent years, with RPM having grown into a multi-billion dollar market since the first CPT codes in 2019.
iRhythm’s strategic logic is about widening what it can monitor and where. VitalConnect’s FDA-cleared monitoring platform already spans several cardiac modalities plus multi-vitals capabilities built for hospital and remote-care settings.
- This, in turn, extends iRhythm’s reach across the continuum of care by adding mobile cardiac telemetry (MCT), a large and growing RPM category, to Zio’s portfolio.
- Moreover, VitalConnect’s biosensor platform can track up to 11 physiological parameters, pushing iRhythm into inpatient and hospital-to-home segments.
iRhythm is framing this acquisition as complementary, not redundant. Rather than replacing its flagship Zio, the company positions VitalConnect as filling gaps Zio doesn’t.
- Since ambulatory monitoring isn’t one-size-fits-all, clinical needs, workflows, and patient preferences vary, and different use cases call for different monitoring models.
- The combination is meant to give clinicians more choice across settings through iRhythm’s commercial scale, while accelerating VitalConnect’s growth.
The move comes at a time when education is key. Though MCT and the broader RPM category have shown immense potential for arrhythmia detection and post-stroke or post-ablation monitoring, the cardiology community has been slow to adopt it.
- Hurdles like clinical workloads, EHR integrations, and overall process complexity act as an adoption barrier for iRhythm and VitalConnect’s technologies.
- So while this expansion is a big move for iRhythm, it will still have to work to convince cardiologists that the juice is worth the squeeze.
The Takeaway
Acquisitions can be a sign of a maturing market, and in the case of iRhythm’s RPM model, bringing VitalConnect into the fold makes perfect sense. Whether or not the expansion into MCT will pay off is a matter of physician perception.
